Development of oral insulin: progress and current status

NOBEX oral drug delivery technology is centered on modification of peptides, proteins and small organic molecules by attachment of one or more amphiphilic oligomers. Attachment of these oligomers results in stability to enzymatic degradation, improved solubility to allow optimized formulation, and m...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes/metabolism research and reviews 2002-01, Vol.18 (S1), p.S29-S37
Main Author: Gordon Still, J.
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
Blood Glucose - metabolism
diabetes
Diabetes Mellitus, Type 1 - drug therapy
Diabetes Mellitus, Type 1 - metabolism
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Drug Delivery Systems
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - metabolism
insulin
Insulin - administration & dosage
Insulin - metabolism
oral insulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NOBEX oral drug delivery technology is centered on modification of peptides, proteins and small organic molecules by attachment of one or more amphiphilic oligomers. Attachment of these oligomers results in stability to enzymatic degradation, improved solubility to allow optimized formulation, and modification of pharmacology to prolong circulating half‐life and activity. NOBEX has applied this technology to insulin, creating an orally absorbed, bioactive conjugate which is safe and rapidly absorbed and which demonstrates dose‐dependent, glucose‐lowering effects in animal models, healthy volunteers and type 1 diabetic patients. Results of recently completed and ongoing studies in both type 1 and type 2 diabetes suggest a promising role for conjugated insulin in the management of fasting and post‐prandial hyperglycemia. Orally administered conjugated insulin is delivered first to the liver through the portal circulation, similar to the physiological route of insulin secretion in non‐diabetic individuals. Potential benefits from this route of insulin delivery include improved disease management and reduction of long‐term complications of diabetes. Further studies with oral conjugated insulin are planned in both type 1 and type 2 diabetic patients. Copyright © 2002 John Wiley & Sons, Ltd.
ISSN:1520-7552
1520-7560
DOI:10.1002/dmrr.207